Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

Abstract Background Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was cardioprotective in this population. The...

Full description

Bibliographic Details
Main Authors: Subha V. Raman, Kan N. Hor, Wojciech Mazur, Xin He, John T. Kissel, Suzanne Smart, Beth McCarthy, Sharon L. Roble, Linda H. Cripe
Format: Article
Language:English
Published: BMC 2017-02-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Cardiomyopathy
Eplerenone
Mineralocorticoid receptor antagonist
Duchenne
Muscular dystrophy
Online Access:http://link.springer.com/article/10.1186/s13023-017-0590-8

Internet

http://link.springer.com/article/10.1186/s13023-017-0590-8

Similar Items